Bio Green Med Solution (BGMS) Gross Margin (2010 - 2026)

Bio Green Med Solution (BGMS) posted quarterly Gross Margin of 18.38% for Q1 2026, down 97.62% quarter-over-quarter from 772.84% in Q4 2025.

Analysis

Bio Green Med Solution (BGMS) Gross Margin (2010 - 2026) Analysis & Trends

Bio Green Med Solution (BGMS) has reported Gross Margin for 5 consecutive years, with 18.38% the latest figure, recorded in Q1 2026.

In Q1 2026, Gross Margin changed N/A year-over-year to 18.38%; the TTM figure through Mar 2026 stood at 69.15% (changed N/A YoY), while the FY2011 annual figure was 48.5%, up 36650.0% from the prior year.
Gross Margin retreated to 18.38% in Q1 2026 per BGMS's latest filing, from 772.84% in the prior quarter.
Across five years, Gross Margin topped out at 772.84% in Q4 2025 and bottomed at 18.38% in Q1 2026.

Peer Set

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Gross Margin (Qtr)
1	Vertex Pharmaceuticals	141.56 Bn	133.71 Bn	2.84 Bn	85.33%
2	Regeneron Pharmaceuticals	87.63 Bn	79.64 Bn	3.93 Bn	91.59%
3	Argenx Se	64.65 Bn	59.46 Bn	1.37 Bn	90.43%
4	Moderna	60.24 Bn	55.10 Bn	52.00 Mn	35.86%
5	Revolution Medicines	44.13 Bn	44.13 Bn	-	-
6	BeOne Medicines	40.46 Bn	35.36 Bn	1.53 Bn	89.76%
7	Alnylam Pharmaceuticals	35.86 Bn	32.56 Bn	992.69 Mn	76.90%
8	Royalty Pharma	28.00 Bn	27.16 Bn	-	-
9	Insmed	27.40 Bn	26.24 Bn	358.27 Mn	84.20%
10	Bio Green Med Solution	4.68 Mn	886,595.10	79,000.00	23.51%

Historic Data

Download Data